Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study

International Journal of Antimicrobial Agents

Volumn 45, Issue 4, 2015, Pages 385-392

  Huttner, Angela ^a   Von Dach, Elodie ^a   Renzoni, Adriana ^a   Huttner, Benedikt D ^a   Affaticati, Mathieu ^b   Pagani, Leonardo ^a   Daali, Yousef ^a   Pugin, Jerôme ^a   Karmime, Abderrahim ^a   Fathi, Marc ^a   Lew, Daniel ^a   Harbarth, Stephan ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antibacterial agents; Augmented renal clearance; Carbapenems; Critically ill; Therapeutic drug monitoring; Lactam antibiotics

Indexed keywords

BETA LACTAM; CEFEPIME; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; AUGMENTED KIDNEY CLEARANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; ADOLESCENT; BACTERIAL INFECTIONS; CRITICAL ILLNESS; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925484962     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.12.017     Document Type: Article

References (23)

1. H. Eagle, R. Fleischman, and A.D. Musselman The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms Ann Intern Med 33 1950 544 571
2. J.D. Turnidge The pharmacodynamics of β-lactams Clin Infect Dis 27 1998 10 22
3. B.A. Christensson, I. Nilsson-Ehle, M. Hutchison, S.J. Haworth, B. Oqvist, and S.R. Norrby Pharmacokinetics of meropenem in subjects with various degrees of renal impairment Antimicrob Agents Chemother 36 1992 1532 1537
4. J. Cronqvist, I. Nilsson-Ehle, B. Oqvist, and S.R. Norrby Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment Antimicrob Agents Chemother 36 1992 2676 2680
5. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B.C. McWhinney, and J.P. Ungerer Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 142 2012 30 39
6. A.A. Udy, J.A. Roberts, R.J. Boots, D.L. Paterson, and J. Lipman Augmented renal clearance: implications for antibacterial dosing in the critically ill Clin Pharmacokinet 49 2010 1 16
7. C. Jaccard, N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, and R. Schneider Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis Antimicrob Agents Chemother 42 1998 2966 2972
8. S. Harbarth, D. Pittet, V. Gabriel, J. Garbino, and D. Lew Cefepime - assessment of its need at a tertiary care center J Clin Pharm Ther 23 1998 11 17
9. G. Zanetti, S.J. Harbarth, A. Trampuz, M. Ganeo, F. Mosimann, and R. Chautemps Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections Int J Antimicrob Agents 11 1999 107 113
10. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. M. Dreetz, J. Hamacher, J. Eller, K. Borner, P. Koeppe, and T. Schaberg Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin Antimicrob Agents Chemother 40 1996 105 109
12. Swiss Medical Compendium. 〈http://www.compendium.〉 [accessed January 2014].
13. P. Van der Auwera, and P.J. Santella Pharmacokinetics of cefepime: a review J Antimicrob Chemother 32 1993 S103 S115
14. T.P Lodise Jr., B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
15. European Committee on Antimicrobial Susceptibility Testing. 〈http://www.eucast.org/clinical-breakpoints/〉
16. J.A. Roberts, R. Boots, C.M. Rickard, P. Thomas, J. Quinn, and D.M. Roberts Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care?. A randomized controlled pilot study J Antimicrob Chemother 59 2007 285 291
17. B.O. Claus, E.A. Hoste, K. Colpaert, H. Robays, J. Decruyenaere, and J.J. De Waele Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy J Crit Care 28 2013 695 700
18. J.A. Roberts, S.K. Paul, M. Akova, M. Bassetti, J.J. De Waele, G. Dimopoulos DALI Study DALI: Defining Antibiotic Levels in Intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 2014 1072 1083
19. ∗ Crit Care Med 42 2014 520 527
20. J.P. Baptista, L. Teixeira, L. Rodrigues, M. Neves, and J. Pimentel Augmented creatinine renal clearance in critically ill patients: is there a place for a new prognostic marker? Intensive Care Med 38 2012 S298
21. B. Fantin, X. Duval, L. Massias, L. Alavoine, F. Chau, and S. Retout Ciprofloxacin dosage and emergence of resistance in human commensal bacteria J Infect Dis 200 2009 390 398
22. A.D. Rule, T.S. Larson, E.J. Bergstralh, J.M. Slezak, S.J. Jacobsen, and F.G. Cosio Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease Ann Intern Med 141 2004 929 937
23. J.P. Baptista, A.A. Udy, E. Sousa, J. Pimentel, L. Wang, and J.A. Roberts A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance Crit Care 15 2011 R139